COVID-19药物治疗的安全性考量与耳毒性:叙述性综述
该叙述性综述通过检索ClinicalTrials.gov和PubMed数据库,总结了潜在COVID-19治疗药物的耳毒性证据。共识别出六种具有耳毒性副作用的药物,包括氯喹/羟氯喹、阿奇霉素、洛匹那韦-利托那韦、干扰素、利巴韦林和伊维菌素。结论认为停药可能改善或减轻耳毒性效应,建议对接受已知耳毒性药物治疗的患者(尤其老年和听力受损高危人群)考虑听力监测方案。
要点
- 六种COVID-19候选治疗药物具有耳毒性副作用
- 停药可能改善或减轻耳毒性效应
- 识别听力损失、耳鸣或失衡/眩晕对早期干预至关重要
核心结论
- 现有证据提示,停用耳毒性药物可能改善或减轻耳毒性效应。
- 识别听力损失、耳鸣或失衡/眩晕对于促进早期干预和预防长期损害至关重要。
- 医院应考虑对接受已知耳毒性COVID-19治疗药物的患者纳入听力监测方案,尤其是老年和听力受损等高危人群。
研究设计与样本
- 叙述性综述,通过ClinicalTrials.gov和PubMed数据库检索COVID-19候选治疗药物,并针对每种药物在PubMed进行文献回顾以识别耳毒性相关文章。
主要发现
- 共识别出六种具有耳毒性副作用的COVID-19候选治疗药物:氯喹和羟氯喹、阿奇霉素、洛匹那韦-利托那韦、干扰素、利巴韦林和伊维菌素。
临床怎么用
- 临床应识别接受上述药物治疗患者的听力损失、耳鸣或失衡/眩晕症状,以便早期干预。
- 对接受已知耳毒性药物治疗的患者,尤其老年和听力受损者,医院应考虑纳入听力监测方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/HYPOTHESIS: The purpose of this review is to summarize evidence-based data regarding the ototoxic effects of potential COVID-19 therapeutics to treat patients suffering from SARS-CoV-2. METHODS: Medications under investigation as novel therapeutics to treat COVID-19 were identified using the search term coronavirus therapeutics, COVID therapeutics, and SARS-CoV-2 therapeutics on ClinicalTrials.gov and the PubMed Database. A literature review was performed using the PubMed Database for each proposed COVID-19 therapeutic to identify relevant articles. Search criteria included Medical Subject Headings (MeSH) and key word search terms for ototoxicity, vestibulotoxicity, hearing disorders, and vertigo. RESULTS: Six proposed COVID-19 therapeutics were identified as possessing ototoxic side effects including chloroquine and hydroxychloroquine, azithromycin, lopinavir-ritonavir, interferon, ribavirin, and ivermectin. CONCLUSIONS: Available evidence suggests that ototoxic effects may be improved or mitigated by stopping the offending agent. Recognition of hearing loss, tinnitus, or imbalance/vertigo is therefore crucial to facilitate early intervention and prevent long-term damage. Hospitals should consider the inclusion of audiologic monitoring protocols for patients receiving COVID-19 therapeutics with known ototoxicity, especially in high-risk patient groups such as the elderly and hearing impaired. Laryngoscope, 131:1626-1632, 2021.
引用
- Little C, Cosetti MK. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. Laryngoscope. 2021. PMID: 33491234. doi:10.1002/lary.29424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。